Some commercial gene-panel tests for hereditary breast-ovarian cancer already include PALB2. However, whether there is clinical utility in testing unaffected women for deleterious mutations in PALB2 is not clear given the uncertainties in the risk estimates for this gene. The gene discussed is PALB2; the disease is Hereditary breast and ovarian cancer syndrome.